Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
5 results
  • Cervical Cancer, Gastric (Stomach) Cancer, Liver Cancer

20-577          Phase I

A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors (View details on clinicaltrial.gov)

  • Breast Cancer, Head and Neck Cancer, Cervical Cancer, Ovarian Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer (View details on clinicaltrial.gov)

  • Head and Neck Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Cervical Cancer, Esophageal Cancer

22-281          Phase I

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors (View details on clinicaltrial.gov)

  • Breast Cancer, Ovarian Cancer, Cervical Cancer, Pancreatic Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Esophageal Cancer, Endometrial Cancer, Lung Cancer

22-015          Phase I

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a SA and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (View details on clinicaltrial.gov)

  • Chordoma, Melanoma, Cervical Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Bladder Cancer

20-650          Phase II

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology (View details on clinicaltrial.gov)

Showing 1 - 10 of 5 results